Ligand ID: 40L Drugbank ID: DB09054(Idelalisib) Indication:Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | PRO A 378ILE A 539ASP A 684THR A 565ASN A 568 | 1.78A | 21.84 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE C 203TYR C 204VAL C 193ASP C 88ASP C 228 | 1.73A | 20.51 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PRO B1069TYR C 904VAL B1094ASN B1074ILE C 896 | 1.64A | 20.92 | NoneNoneNoneNAG B1316 (-1.9A)None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PRO B1069TYR C 904VAL B1094ASN B1074ILE C 896 | 1.65A | 20.92 | NoneNoneNoneNAG B1314 (-1.9A)None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6w41 | CR3022 FAB LIGHTCHAINSPIKE PROTEIN S1 (Homosapiens;SARS-CoV-2) | 5 / 12 | PRO C 412TYR L 32VAL L 27ASP L 1THR L 94 | 1.70A | 10.52 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ILE A 306ASP A 324THR A 275ASN A 75ILE A 296 | 1.68A | 16.58 | None |